Table of Contents
ISRN Dermatology
Volume 2012, Article ID 308279, 7 pages
http://dx.doi.org/10.5402/2012/308279
Review Article

Malignant Melanoma

Department of Nuclear Medicine, Clinico San Carlos Hospital, 28040 Madrid, Spain

Received 22 October 2012; Accepted 7 November 2012

Academic Editors: S.-C. Chao, M. Feinmesser, and Y. Tuzun

Copyright © 2012 Aída Ortega Candil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nuclear medicine plays an essential role in the correct staging of patients suffering from melanoma. Both sentinel lymph node biopsy (SLNB) and positron emission tomography (PET) represent its main diagnostic tools. SLNB is the choice procedure for lymphatic regional staging of these patients, including the result of this technique in the 2002 American Joint Cancer Committee melanoma staging. SLNB sensitivity is superior than PET/CT for the detection of lymphatic micrometastases in early stages of the disease. PET/CT is mainly used in confirming clinical metastases suspected, detection of recurrences, and recurrence restaging. PET/CT has also shown superiority against conventional diagnostic methods in the detection of distant metastases, being able to detect illness even six months earlier than those methods.